SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels post-earnings selloff is centered on a weaker-than-expected Q4 outlook, with traders pointing to soft PC demand and manufacturing constraints despite a stronger Q3 showing; the Fab 28 disruption is also cited as a headwind. The community is split between dip-buyers calling the drop an overreaction and bearish traders focused on delayed growth, execution concerns, and analyst downgrades.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention after strong quarterly results and an upbeat outlook failed to prevent a sharp drop, alongside an announced 8-for-1 split and a broader chip selloff. Traders debate whether the decline is profit-taking and market-wide pressure or a warning that memory pricing may be nearing a cyclical peak.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook have sparked a sharp selloff, with traders focused on heavy AI infrastructure spending and negative free cash flow despite accelerating AWS growth. The debate is whether cloud demand and future returns justify the spending: some see the drop as overdone and are buying the dip, while others worry about cash burn and delayed payback.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits post-earnings selloff is centered on weaker-than-expected Q4 guidance, slowing user growth and declining Google search referrals, alongside plans to test a logged-in-only experience. Traders worry those changes could further reduce traffic and ad reach, while others view the drop as an overreaction to an otherwise strong quarter and see a buying opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is drawing attention after a reported major Binance security breach prompted a crypto selloff and renewed concerns about exchange security. Traders disagree over whether the incident signals broader risk to crypto or is limited to a centralized exchange, with some viewing the pullback as a buying opportunity and others warning of further declines.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led selloff following disappointing Intel guidance and Amazons heavy AI spending has intensified concerns that Big Techs capital expenditures may not deliver adequate returns, weighing on QQQ. Traders are split between calling it an AI-bubble unwind with further downside and viewing the decline as a buying opportunity or potential bounce.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention after a steep retreat from silvers January peak, with persistent selling and a break below the closely watched $50 area prompting traders to debate where support may form. Many expect further losses, while others see oversold conditions and are buying dips; explanations range from higher yields and profit-taking to unsubstantiated claims of market manipulation.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases quarterly results sparked debate: traders noted the headline profit beat but questioned its quality because much of it came from gains on crypto holdings while operating income and transaction revenue weakened. Concern over reports of a major Binance security breach and the resulting crypto-market pressure added to bearish sentiment, though some see Coinbase as a potential beneficiary because its own platform was not reported hacked.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias Q3 results and higher full-year revenue guidance are driving attention, with traders pointing to continued LUPKYNIS growth and profitability. Reactions are mixed: some call the report strong, while others question the lack of sequential sales growth and another earnings release without a call, alongside volatile trading.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its delivery outlook as the R2 ramp gains traction, drawing bullish reactions from traders. The enthusiasm is tempered by frustration over muted share performance and concerns about continued losses, cash burn, and the path to profitability.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline

BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC Q3 Earnings Preview: Here's What You Should Know 

Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.

Harmony Biosciences Holdings Enters Oversold Territory (HRMY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

HRMY or ARGX: Which Is the Better Value Stock Right Now?

HRMY vs. ARGX: Which Stock Is the Better Value Option?

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Harmony Biosciences Holdings Inc

Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.</li><li>It announced second-quarter preliminary net product revenue for WAKIX (pitolisant) of approximately $261 million.</li><li>CEO Jeffrey M. Dayno stated that the record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business.</li></ul>Shares of Harmony Biosciences Holdings, Inc. (HRMY) drew significant investor attention on Thursday after the company reported its preliminary second-quarter revenue and announced that its CFO, Glenn Reicin, has stepped down to pursue other opportunities effective July 16.As of this writing, HRMY shares traded over 5% lower on Thursday morning. The stock hit its 200-day moving average (DMA) and bounced back, paring some of the early morning losses.<h2 class="st-heading-2">HRMY’s CFO Transition</h2>Harmony announced that it appointed Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer, to ensure continuity in financial leadership as it searches for a permanent CFO.Harmony also stated that the CFO’s departure is not due to any disagreement with the firm. “Mr. Reicin’s departure is not the result of any disagreement with the company on any matter relating to its operations, policies or practices, and Harmony does not expect this transition to affect its performance or momentum in any way,” the firm stated.<h2 class="st-heading-2">HRMY Announces Preliminary Figures</h2>The company reaffirmed its full-year 2026 net product revenue guidance of $1 billion to $1.04 billion. It announced preliminary second-quarter (Q2) net product revenue for WAKIX (pitolisant) of approximately $261 million, which it said is a new quarterly revenue record and marks 30% year-over-year growth and 21% quarter-over-quarter growth.CEO Jeffrey M. Dayno stated that the record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business.“Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion.”Harmony is scheduled to report its Q2 results on August 4.Meanwhile, retail sentiment surrounding HRMY stock on Stocktwits turned ‘neutral’ from ‘bearish’ a day ago, amid moderate chatter.<a href="https://stocktwits.com/symbol/HRMY">HRMY</a> shares have lost over 11% this year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/aapl-china-memory-chip-plan-national-security-subsidize-pla/cZZEOKTR7sf">AAPL's China Memory Chip Plans Draw National Security Scrutiny — Lawmakers Say Every Memory Chip Purchase Will Subsidize PLA</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Image for representational purpose. A view from lab as Ankara University Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences.

Shares of Harmony Biosciences Holdings, Inc. (HRMY) drew significant investor attention on Thursday after the company reported its preliminary second-quarter revenue and announced that its CFO, Glenn Reicin has stepped down

Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement 

Harmony Biosciences announced the appointment of Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer to ensure continuity in financial leadership while it searches for a permanent CFO.

ProShares Ultra Russell2000

Vanguard Group, Inc. - Vanguard U.S. Multifactor ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$HRMY $SSRM $HESM — three Neutral names on the watchlist. One real conflict. 
 
**$HRMY:** Fundamentals A, Technicals B, near 52W high. Wall Street Buy (2.3/5). But insiders sold $1.2M, no buys. Institutions trimmed 3.2%. Nothing broken, nothing confirming. 
 
$SSRM: Fundamentals A, Technicals B, 5-10% below high. Wall Street Buy (1.6/5, +31%). Institutions adding +2.1%. Insiders quiet. Layers point same way — quietly. 
 
$HESM: Down 24.2% from high. Historical drawdown pattern: 5/5 recovered within 3 months (median +9.8%). But Wall Street says Sell (3.6/5). Institutions trimming 1.3%. 
 
History says recover. Street says no. That's why it's on the watchlist. 
 
NFA.

Evgeniy Mezenov

Magic Formula card 🃏 $HRMY 
Narcolepsy drug maker posted a record quarter:  
Q2 2026 sales ~$261M, +30% y/y. 
Would you own it? Not investment advice.

Feed

News

Sentiment

Earnings

Fundamentals

Info

HRMY Harmony Biosciences Holdings Inc

Fundamentals

Latest HRMY News